Funding to scale production, research, and global footprint

ELMED Life Sciences has secured $2.7 million (around Rs 25.4 crore) in a Series A funding round led by the AgriSURE Fund, managed by NABVENTURES, as it looks to strengthen its position in the rapidly growing microbiome solutions segment.

The company intends to use the funds to increase its production capacity at its Hyderabad facility and enhance its research efforts focused on microbiome-based innovations. A portion of the capital will also support expansion into new markets within India and overseas.

Established in 2018 by Pruthivin Reddy Madduri and Nikhil Konkathi, ELMED operates as a probiotic-focused manufacturer, offering contract production and research services to companies in the healthcare and agri-biotech sectors. Its solutions cater to a wide range of applications, including human health, animal care, aquaculture, and crop systems.

Microbiome technologies, which focus on managing microbial ecosystems such as bacteria and fungi, are increasingly being adopted as sustainable alternatives across industries. These approaches aim to improve overall system balance and resilience through targeted biological interventions.

With the new funding, ELMED plans to upgrade its manufacturing capabilities to produce probiotics in multiple formats, including suspensions, capsules, sachets, emulsions, and syrups. This expansion is expected to improve scalability and support rising demand from both domestic and international clients.

The company is also looking to strengthen its distribution network, particularly in Tier II and Tier III markets in India, while expanding its footprint globally. At present, ELMED exports to over 18 countries and aims to deepen its presence across regions such as Europe, Asia, and Latin America.

The funding comes at a time when interest in microbiome-based solutions is gaining momentum, driven by increasing awareness of biologically driven and sustainable alternatives. Investors are showing growing interest in startups operating at the intersection of biotechnology, agriculture, and healthcare.

With this latest round, ELMED aims to accelerate its growth trajectory and build a stronger presence in the global microbiome ecosystem.